The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.

Background: Glioblastoma patients show a great variability in progression free survival (PFS) and overall survival (OS). To gain additional pretherapeutic information, we explored the potential of O-(2-F-fluoroethyl)-L-tyrosine (FET) PET as an independent prognostic biomarker.

Methods: We retrospectively analyzed 146 consecutively treated, newly diagnosed glioblastoma patients.